Molecular Cancer Therapeutics · 2011 · 27 citations · 28 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingMalignant NeoplasmsOncogenic Signaling PathwaysOvarian CancerOvarian Cancer PharmacotherapySignal Transduction In CancerCancer Signaling PathwaysEgfr InhibitionErk SignalingErlotinib TherapyExtracellular Signal-regulated Kinase PathwayExtracellular Signal-regulated Kinase SignalingMitogenic Signaling PathwaysTyrosine Kinase Inhibitor Therapy
Clear cell carcinoma (CCC) of the ovary tends to show resistance to standard chemotherapy, which results in poor survival for patients with CCC. Developing a novel therapeutic strategy is imperative to improve patient prognosis. Epidermal growth factor receptor (EGFR) is frequently expressed in epithelial ovarian cancer. One of the major downstream targets of the EGFR signaling cascade is extracellular signal-related kinase (ERK). PEA-15, a 15-kDa phosphoprotein, can sequester ERK in the cytoplasm. MEK1/2 plays a central role in integrating mitogenic signals into the ERK pathway. We tested the hypothesis that inhibition of the EGFR-ERK pathway suppresses tumorigenicity in CCC, and we investigated the role of PEA-15 in ERK-targeted therapy in CCC. We screened a panel of 4 CCC cell lines (RMG-I, SMOV-2, OVTOKO, and KOC-7c) and observed that the EGFR tyrosine kinase inhibitor erlotinib inhibited cell proliferation of EGFR-overexpressing CCC cell lines through partial dependence on the MEK/ERK pathway. Furthermore, erlotinib-sensitive cell lines were also sensitive to the MEK inhibitor selumetinib (AZD6244), which is under clinical development. Knockdown of PEA-15 expression resulted in reversal of selumetinib-sensitive cells to resistant cells, implying that PEA-15 contributes to selumetinib sensitivity. Both selumetinib and erlotinib significantly suppressed tumor growth (P < 0.0001) in a CCC xenograft model. However, selumetinib was better tolerated; erlotinib-treated mice exhibited significant toxic effects (marked weight loss and severe skin peeling) at high doses. Our findings indicate that the MEK-ERK pathway is a potential target for EGFR-overexpressing CCC and indicate that selumetinib and erlotinib are worth exploring as therapeutic agents for CCC.
28
Clinical characteristics of clear cell carcinoma of the ovary
Toru Sugiyama, Toshiharu Kamura, Junzo Kigawa et al. · Cancer · 2000 · 804 citations
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
Jer-Yen Yang, Cong S. Zong, Weiya Xia et al. · Nature Cell Biology · 2008 · 699 citations
Alex A. Adjei, Roger B. Cohen, Wilbur A. Franklin et al. · Journal of Clinical Oncology · 2008 · 573 citations · Full text
Medicine, Oncology, Pharmacology +17